Geographic atrophy

Complement Therapeutics (CTx) has enrolled the first patient in its study of people diagnosed with geographic atrophy (GA).  The research will support the clinical development of CTx001, CTx’s lead gene therapy asset for the treatment of GA, by enabling the identification of patients with complement-driven AMD for future interventional studies.  Also called late dry age-related macular […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In a week that saw magic mushrooms making the headlines in the UK, we also reported on exciting potential new […]

News round-up for 31 October – 4 November by DDW Digital Content Editor Diana Spencer  In a week that saw magic mushrooms making the headlines in the UK, we also reported on exciting potential new therapies for geographic atrophy and malaria prevention. Meanwhile, the quest to understand Covid-19 continues, as study findings reveal how the […]

Complement Therapeutics’ lead asset CTx001, an AAV-based gene therapy for the treatment of geographic atrophy (GA), has been awarded an Innovation Passport by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA).  CTx001 was awarded the Innovation Passport based on three criteria: that the condition addressed is seriously debilitating with a significant patient need; an […]

Results from Phase I/II MGT009 study into investigational gene therapy botaretigene sparoparvovec suggest sustained vision improvement in patients with X-linked retinitis pigmentosa (XLRP).  The study found treatment with botaretigene sparoparvovec had an acceptable safety profile and demonstrated encouraging improvements in retinal sensitivity, visual function and functional vision.  The late-breaking results were revealed at the American […]

Biotechnology company Complement Therapeutics (CTx) has formed a Clinical & Scientific Advisory Board to help accelerate the development of its pipeline of therapeutics targeting complement-mediated diseases. The company’s lead investigational product, CTx001, is a gene therapy for dry age-related macular degeneration/geographic atrophy, which is a leading cause of blindness. The company hopes to evaluate CTx001 […]